Paracetamol/Kofein Xantis 500 mg/65 mg šumivé tablety 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

paracetamol/kofein xantis 500 mg/65 mg šumivé tablety

xantis pharma limited, cyprus - paracetamol, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Paracetamol/Kofein Dr. Müller Pharma 500 mg/65 mg tablety 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

paracetamol/kofein dr. müller pharma 500 mg/65 mg tablety

dr. müller pharma s.r.o., Česká republika - paracetamol, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Paracetamol/Kofein Dr. Müller Pharma 1000 mg/130 mg tablety 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

paracetamol/kofein dr. müller pharma 1000 mg/130 mg tablety

dr. müller pharma s.r.o., Česká republika - paracetamol, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Mapoli 25 mg/ml perorálny roztok 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mapoli 25 mg/ml perorálny roztok

glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Kauliv 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teriparatid - osteoporosis; osteoporosis, postmenopausal - homeostáza vápnika - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Teriparatide Sun 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - homeostáza vápnika - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.